TNFRSF17 and Miyoshi myopathy: described pseudoprogression in a patient who received anti‐B‐cell maturation antigen (BCMA) CAR T‐cell therapy (idecabtagene vicleucel) and a G protein‐coupled receptor, class C, group 5, member D (GPRC5D) × cluster of differentiation 3 (CD3) bispecific antibody (talquetamab), yet this phenomenon has not been reported with anti‐BCMA bispecific antibodies in MM [8, 9].